Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).
A number of cancer therapy agents are cleared by the kidney and may affect renal function, including cytotoxic chemotherapy agents, molecular targeted therapies, analgesics, antibiotics, radiopharmaceuticals and radiation therapy, and bone-targeted therapies. Many of these agents can be nephrotoxic, including targeted cancer therapies. The incidence, severity, and pattern of renal toxicities may vary according to the respective target of the drug. Here, we review the renal effects associated with a selection of currenty approved targeted cancer therapies, directed to vascular endothelial growth factor or VEGF receptor(s) (VEGF/VEGFR), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor2 (HER2), BRAF, anaplastic lymphoma kinase (ALK), programmed cell death protein-1 or its ligand (PD-1/PDL-1), receptor activator of nuclear factor kappa-B ligand (RANKL), and mammalian target of rapamycin (mTOR). The early diagnosis and prompt treatment of these renal alterations are essential in the daily practice where molecular targeted therapies have a definitive role in the armamentarium used in many cancers.
Cancer & the Kidney International Network (C-KIN), Brussels Service ICAR, Pitié-Salpêtrière University Hospital, Paris vincent.launay-vacher@psl.aphp.fr.
V
V
Launay-Vacher
Cancer & the Kidney International Network (C-KIN), Brussels Multidisciplinary Oncology Institute, Genolier Clinic, Genolier, Switzerland.
M
M
Aapro
Cancer & the Kidney International Network (C-KIN), Brussels Department of Clinical Oncology, Sao Paulo State Cancer Institute, Sao Paulo, Brazil.
G
G
De Castro
Cancer & the Kidney International Network (C-KIN), Brussels Nephrology Section, Zablocki Veterans Affair Medical Center, Milwaukee, USA.
E
E
Cohen
Cancer & the Kidney International Network (C-KIN), Brussels Department of Nephrology, Pitié-Salpêtrière University Hospital, Paris, France.
G
G
Deray
Cancer & the Kidney International Network (C-KIN), Brussels Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Parkville, Australia.
M
M
Dooley
Cancer & the Kidney International Network (C-KIN), Brussels Renal Division, Brigham and Women's Hospital, Boston.
B
B
Humphreys
Cancer & the Kidney International Network (C-KIN), Brussels Clinical Geriatrics Program, Memorial Sloan-Kettering Cancer Center, New-York, USA.
S
S
Lichtman
Cancer & the Kidney International Network (C-KIN), Brussels Department of Pharmacy, Jean Godinot Cancer Institute, Reims.
J
J
Rey
Cancer & the Kidney International Network (C-KIN), Brussels Supportive Care in Cancer Unit, Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France.
F
F
Scotté
Cancer & the Kidney International Network (C-KIN), Brussels Department of General Medicine, University Hospitals Leuven, Leuven.
H
H
Wildiers
Cancer & the Kidney International Network (C-KIN), Brussels Department of Nephrology, UZ Leuven, Leuven, Belgium.
B
B
Sprangers
D000077548:Anaplastic Lymphoma Kinase; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D058990:Molecular Targeted Therapy / Q000009:adverse effects; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D053245:RANK Ligand / Q000037:antagonists & inhibitors; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
D000077548:Anaplastic Lymphoma Kinase; D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D047428:Protein Kinase Inhibitors; D048493:Proto-Oncogene Proteins B-raf; D053245:RANK Ligand; D020794:Receptor Protein-Tyrosine Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor; D058570:TOR Serine-Threonine Kinases; C000626173:ALK protein, human
cancer; kidney disease; molecular targeted therapy; nephrotoxicity; renal failure; renal toxicity